ArticleEvolutionary applications2020
Evolution of antibiotic cross-resistance and collateral sensitivity in
Article in Evolutionary applications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Evolutionary drivers of divergent collateral sensitivity responses during antibiotic therapy.Nature ecology & evolution · 2026Review
- Synergistic effect and resistance prevention activity of antimicrobial peptide MPX with Tulathromycin againstFrontiers in microbiology · 2026Article
- Tripartite Loops Reverse Antibiotic Resistance.Molecular biology and evolution · 2025Article
- Interactions within higher-order antibiotic combinations do not influence the rate of adaptation in bacteria.Evolution; international journal of organic evolution · 2025Article
- Development of bacterial resistance in Germany from 2008 to 2022 - major culprit pathogens, antibacterial drugs, and prescribing practices.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Survival, resistance, and fitness dynamics ofEvolution, medicine, and public health · 2025Article
- Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.BMC veterinary research · 2024Article
- Navigating collateral sensitivity: insights into the mechanisms and applications of antibiotic resistance trade-offs.Frontiers in microbiology · 2024Review
- Susceptibility evaluation and PK/PD integration of tulathromycin againstFrontiers in veterinary science · 2024Article
- The evolution of resistance to synergistic multi-drug combinations is more complex than evolving resistance to each individual drug component.Evolutionary applications · 2023Article
- Alteration ofMicrobiology spectrum · 2023Article
- Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Bayesian network modeling of patterns of antibiotic cross-resistance by bacterial sample source.Communications medicine · 2023Article
- Effect of Antibiotic Exposure onInternational journal of molecular sciences · 2023Article
- Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models.Frontiers in veterinary science · 2022Review
- Acquisition of Daptomycin Resistance byFrontiers in microbiology · 2022Article
- Antifungal Activity of a Medical-Grade Honey Formulation againstJournal of fungi (Basel, Switzerland) · 2021Article
- Acquisition of Tigecycline Resistance by Carbapenem-ResistantFrontiers in microbiology · 2021Article
- Systematic Investigation of Resistance Evolution to Common Antibiotics Reveals Conserved Collateral Responses across Common Human Pathogens.Antimicrobial agents and chemotherapy · 2020Article
- Evolution of antibiotic cross-resistance and collateral sensitivity inEvolutionary applications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In bacteria, evolution of resistance to one antibiotic is frequently associated with increased resistance (cross-resistance) or increased susceptibility (collateral sensitivity) to other antibiotics. Cross-resistance and collateral sensitivity are typically evaluated at the minimum inhibitory concentration (MIC). However, these susceptibility changes are not well characterized with respect to the mutant prevention concentration (MPC), the antibiotic concentration that prevents a single-step mutation from occurring. We measured the MIC and the MPC for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.